An innovative cell-based assay for the detection of modulators of soluble guanylate cyclase

Assay and Drug Development Technologies

Volumn 4, Issue 2, 2006, Pages 165-173

  Corazza, Sabrina ^a   Scarabottolo, Lia ^a   Lohmer, Stefan ^a   Liberati, Chiara ^a  

^a Axxam   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 3 (4 AMINO 5 CYCLOPROPYLPYRIMIDINE 2 YL) 1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDINE; 3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CYCLIC AMP; CYCLIC GMP; GUANYLATE CYCLASE; LINSIDOMINE; MUTANT PROTEIN; N ACETYL S NITROSOPENICILLAMINE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALPHA CHAIN; ANIMAL CELL; ARTICLE; BETA CHAIN; BIOLUMINESCENCE; CELL ASSAY; CELL LINE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; MEDICAL RESEARCH; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REPORTER GENE; SENSITIVITY ANALYSIS; STANDARD;

ANIMALS; BIOLOGICAL ASSAY; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC GMP; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATORS; ENZYME INHIBITORS; GUANYLATE CYCLASE; LUMINESCENT MEASUREMENTS; NITRIC OXIDE; PROTEIN BINDING; RATS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33744517191     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2006.4.165     Document Type: Article

References (40)

1. Wedel B, Humbert P, Harteneck C, Foerster J, Malkewitz J, Bohme E, Schultz G, Koesling D: Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc Natl Acad Sci U S A 1994;91:2592-2596.
2. Koesling D, Friebe A: Soluble guanylyl cyclase: structure and regulation. Rev Physiol Biochem Pharmacol 1999;135: 41-65.
3. Budworth J, Meillerais S, Charles I, Powell K: Tissue distribution of the human soluble-guanylate cyclases. Biochem Biophys Res Commun 1999;263:696-701.
4. Furchgott R: Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide [Nobel Lecture]. Angew Chem Int Ed Engl 1999;38:1870-1880.
5. Ignarro LJ: Nitric oxide: a unique endogenous signaling molecule in vascular biology [Nobel Lecture]. Angew Chem Int Ed Engl 1999;38:1882-1892.
6. Murad F: Discovery of some of the biological effects of nitric oxide and its role in cell signaling [Nobel Lecture]. Angew Chem Int Ed Engl 1999;38:1857-1868.
7. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
8. Garthwaite J, Boulton CL: Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995;57:683-706.
9. Sanders KM, Ward SM: Nitric oxide as a mediator of nonadrenergic noncholinergic neurotransmission. Am J Physiol 1992;262:G379-G392.
10. Patel S, Robb-Gaspers LD, Stellato KA, Shon M, Thomas AP: Coordination of calcium signalling by endothelial-derived nitric oxide in the intact liver. Nat Cell Biol 1999;1:467-471.
11. Lincoln TM: Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther 1989;41:479-502.
12. Schwarz UR, Walter U, Eigenthaler M: Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001;62: 1153-1161.
13. Ignarro LJ, Degnan JN, Baricos WH, Kadowitz PJ, Wolin MS: Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta 1982;718: 49-59.
14. Hobbs AJ: Soluble guanylate cyclase: an old therapeutic target re-visited. Br J Pharmacol 2002;136:637-640.
15. Megson IL, Webb DJ: Nitric oxide donor drugs: current status and future trends. Expert Opin Investig Drugs 2002; 11:587-601.
16. Napoli C, Ignarro LJ: Nitric oxide-releasing drugs. Annu Rev Pharmacol Toxicol 2003;43:97-123.
17. Parker JD, Parker JO: Nitrate therapy for stable angina pectoris. N Engl J Med 1998;338:520-531.
18. Gori T, Parker JD: Nitrate tolerance: a unifying hypothesis. Circulation 2002;106:2510-2513.
19. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM: YC-1, a novel activator of platelet guanylate cyclase. Blood 1994;84: 4226-4233.
20. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM: YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 1995;116:1973-1978.
21. Wu CC, Ko FN, Teng CM: Inhibition of platelet adhesion to collagen by cGMP-elevating agents. Biochem Biophys Res Commun 1997;231:412-416.
22. Friebe A, Koesling D: Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998; 53:123-127.
23. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M: NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410: 212-215.
24. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroder H, Schroder W, Stahl E, Steinke W, Wunder F: NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002;136:773-783.
25. Schmidt P, Schramm M, Schroder H, Stasch JP: Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol 2003;468:167-174.
26. Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, Brioni JD: A-350619: a novel activator of soluble guanylyl cyclase. Life Sci 2003;72:1015-1025.
27. Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP: BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 2003;61:464-467.
28. Schuman EM, Madison DV: A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science 1991;254:1503-1506.
29. Chien W-L, Liang K-C, Teng C-M, Kuo S-C, Lee F-Y, Fu W-M: Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. Mol Pharmacol 2003; 63:1322-1328.
30. Smith S, Dringenberg HC, Bennett BM, Thatcher GR, Reynolds JN: A novel nitrate ester reverses the cognitive impairment caused by scopolamine in the Morris water maze. Neuroreport 2000;11:3883-3886.
31. Sunahara RK, Beuve A, Tesmer JJ, Sprang SR, Garbers DL, Gilman AG: Exchange of ubstrate and inhibitor specificities between adenylyl and guanylyl cyclases. J Biol Chem 1998;273:16332-16338.
32. Fink JS, Verhave M, Kasper S, Tsukada T, Mandel G, Goodman RH: The CGTCA sequence motif is essential for biological activity of the vasoactive intestinal peptide gene cAMP-regulated enhancer. Proc Natl Acad Sci U S A 1988;85:6662-6666.
33. Artz JD, Toader V, Zavorin SI, Bennett BM, Thatcher GR: In vitro activation of soluble guanylyl cyclase and nitric oxide release: a comparison of NO donors and NO mimetics. Biochemistry 2001;40:9256-9264.
34. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B: Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996;50:1-5.
35. Bohyn M, Berkenboom G, Fontaine J: Effect of nitrate tolerance and dipyridamole on the response to SIN-1 in the human isolated saphenous vein. Cardiovasc Drugs Ther 1991;5:457-461.
36. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4: 67-73.
37. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP: Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 2004;279:3025-3032.
38. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA: Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.
39. Schults G, Boheme E: In: Methods of Enzymatic Analysis, Vol. 4. Weinheim, Germany: Verlag Chemie, 1984:379-389.
40. Becker EM, Wunder F, Kast R, Robyr C, Hoenicka M, Gerzer R, Schroder H, Stasch JP: Generation and characterization of a stable soluble guanylate cyclase-overexpressing CHO cell line. Nitric Oxide 1999;3:55-66.